Data gathered: December 22
Alternative Data for Evolus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 49 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 23,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 31 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| App Downloads | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 4 | Sign up | Sign up | Sign up |
| Facebook Followers | 7,461 | Sign up | Sign up | Sign up |
| Instagram Followers | 51,689 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,826 | Sign up | Sign up | Sign up |
| Twitter Followers | 687 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 49 | Sign up | Sign up | Sign up |
| Linkedin Employees | 339 | Sign up | Sign up | Sign up |
About Evolus
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
| Price | $10.89 |
| Target Price | Sign up |
| Volume | 979,900 |
| Market Cap | $690M |
| Year Range | $10.45 - $17.49 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
 |
Evolus, Inc.'s (NASDAQ:EOLS) Path To ProfitabilityDecember 19 - Yahoo |
 |
Evolus, Inc. (NASDAQ:EOLS) Position Boosted by Wellington Management Group LLPDecember 18 - ETF Daily News |
|
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stake in Evolus, Inc. (NASDAQ:EOLS)December 17 - ETF Daily News |
|
Fmr LLC Has $1.30 Million Holdings in Evolus, Inc. (NASDAQ:EOLS)December 17 - ETF Daily News |
Evolus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)December 15 - Finnhub |
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 13 - Yahoo |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 61M | 72M | -10M | -19M | -15M | -0.160 |
| Q2 '24 | 67M | 70M | -3.5M | -11M | -6.5M | -0.040 |
| Q1 '24 | 55M | 64M | -9.7M | -13M | -7.2M | -0.090 |
| Q4 '23 | 57M | 63M | -6.5M | -12M | -6.6M | -0.120 |
| Q3 '23 | 46M | 60M | -14M | -17M | -12M | -0.160 |
Insider Transactions View All
| Beaver Sandra filed to sell 148,502 shares at $15. September 6 '24 |
| Yamagishi-Dressler Tomoko filed to sell 82,375 shares at $15.9. September 4 '24 |
| MOATAZEDI DAVID filed to sell 533,349 shares at $12.6. June 6 '24 |
| MOATAZEDI DAVID filed to sell 533,349 shares at $12.9. June 6 '24 |
| MOATAZEDI DAVID filed to sell 533,349 shares at $12.7. June 6 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$144.47 0% | 40 |
 |
Eli Lilly and CompanyLLY |
$767.76 0% | 60 |
 |
PfizerPFE |
$26.36 0% | 41 |
 |
AstrazenecaAZN |
$65.35 0% | 55 |
 |
AbbVieABBV |
$175.58 0% | 60 |
Read more about Evolus (EOLS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, app downloads, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Evolus?
The Market Cap of Evolus is $690M.
What is the current stock price of Evolus?
Currently, the price of one share of Evolus stock is $10.89.
How can I analyze the EOLS stock price chart for investment decisions?
The EOLS stock price chart above provides a comprehensive visual representation of Evolus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Evolus shares. Our platform offers an up-to-date EOLS stock price chart, along with technical data analysis and alternative data insights.
Does EOLS offer dividends to its shareholders?
As of our latest update, Evolus (EOLS) does not offer dividends to its shareholders. Investors interested in Evolus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Evolus?
Some of the similar stocks of Evolus are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.